Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
1.
Circ Arrhythm Electrophysiol ; 17(4): e012022, 2024 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-38415356

RESUMO

BACKGROUND: Germline HRAS gain-of-function pathogenic variants cause Costello syndrome (CS). During early childhood, 50% of patients develop multifocal atrial tachycardia, a treatment-resistant tachyarrhythmia of unknown pathogenesis. This study investigated how overactive HRAS activity triggers arrhythmogenesis in atrial-like cardiomyocytes (ACMs) derived from human-induced pluripotent stem cells bearing CS-associated HRAS variants. METHODS: HRAS Gly12 mutations were introduced into a human-induced pluripotent stem cells-ACM reporter line. Human-induced pluripotent stem cells were generated from patients with CS exhibiting tachyarrhythmia. Calcium transients and action potentials were assessed in induced pluripotent stem cell-derived ACMs. Automated patch clamping assessed funny currents. HCN inhibitors targeted pacemaker-like activity in mutant ACMs. Transcriptomic data were analyzed via differential gene expression and gene ontology. Immunoblotting evaluated protein expression associated with calcium handling and pacemaker-nodal expression. RESULTS: ACMs harboring HRAS variants displayed higher beating rates compared with healthy controls. The hyperpolarization activated cyclic nucleotide gated potassium channel inhibitor ivabradine and the Nav1.5 blocker flecainide significantly decreased beating rates in mutant ACMs, whereas voltage-gated calcium channel 1.2 blocker verapamil attenuated their irregularity. Electrophysiological assessment revealed an increased number of pacemaker-like cells with elevated funny current densities among mutant ACMs. Mutant ACMs demonstrated elevated gene expression (ie, ISL1, TBX3, TBX18) related to intracellular calcium homeostasis, heart rate, RAS signaling, and induction of pacemaker-nodal-like transcriptional programming. Immunoblotting confirmed increased protein levels for genes of interest and suppressed MAPK (mitogen-activated protein kinase) activity in mutant ACMs. CONCLUSIONS: CS-associated gain-of-function HRASG12 mutations in induced pluripotent stem cells-derived ACMs trigger transcriptional changes associated with enhanced automaticity and arrhythmic activity consistent with multifocal atrial tachycardia. This is the first human-induced pluripotent stem cell model establishing the mechanistic basis for multifocal atrial tachycardia in CS.


Assuntos
Células-Tronco Pluripotentes Induzidas , Miócitos Cardíacos , Humanos , Pré-Escolar , Miócitos Cardíacos/metabolismo , Cálcio/metabolismo , Átrios do Coração/metabolismo , Taquicardia , Canais de Cálcio/metabolismo , Células-Tronco Pluripotentes Induzidas/metabolismo , Potenciais de Ação/fisiologia , Diferenciação Celular , Proteínas Proto-Oncogênicas p21(ras)/genética , Proteínas Proto-Oncogênicas p21(ras)/metabolismo
2.
São Paulo; s.n; 2015. [225] p. ilus, tab, graf.
Tese em Português | LILACS | ID: biblio-870781

RESUMO

Os efeitos benéficos associados à injeção intramiocárdica de células-tronco adultas, obtidos em roedores, não tem sido reproduzidos de modo consistente em modelos animais de grande porte e seres humanos. Neste trabalho testamos a hipótese que o transplante de células-tronco mesenquimais derivadas do tecido adiposo de porcos (pASC) aumenta a perfusão tecidual cardíaca em animais infartados e humanizados pelo tratamento com um inibidor da enzima conversora de angiotensina (iECA) e um ?-bloqueador. Os animais foram submetidos a oclusão da artéria coronária circunflexa esquerda (ACX) e 4 semanas após o IM, 4 grupos foram randomizados para receber injeção intramiocárdica de pASC nas doses de 1, 2 ou 4x10 ...


The beneficial effects associated with intramyocardial injection of adult stem cells in rodents have not been consistently reproduced in larger animals and humans. We evaluated the dose of porcine adipose-tissue derived mesenchymal stem cells (pASC) to increase cardiac tissue perfusion in pigs treated with ace-inhibitors and ?-blockers to mimic human management post-MI. Animals were subjected to LCx occlusion and 4 weeks after MI blinded randomized in 4 groups to receive intramyocardial injection of pASC (1, 2 and 4x10 ...


Assuntos
Animais , Bloqueadores do Receptor Tipo 1 de Angiotensina II/uso terapêutico , Células-Tronco Adultas/transplante , Imagem de Perfusão do Miocárdio/métodos , Infarto do Miocárdio/terapia , Inibidores da Enzima Conversora de Angiotensina/uso terapêutico , Tecido Adiposo , Enalapril/uso terapêutico , Metoprolol/uso terapêutico , Suínos
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA